New investment from DRW Venture Capital LLC and Tolmar International Ltd

DRW Venture Capital LLC和Tolmar International Ltd的新投资

Funds will be used to advance its proprietary, silica-based, drug delivery technology platform towards the clinic and further build DelSiTech

资金将用于将其专有的基于二氧化硅的药物输送技术平台推向临床，并进一步建设DelSiTech

TURKU, Finland, Jan. 16, 2024 /PRNewswire/ -- Clinical-stage drug delivery and development company DelSiTech, today announces the successful completion of a EUR 10 million financing round, the largest single financing round in the Company's history. The financing was co-led by new investors DRW Venture Capital LLC, headquartered in Chicago, IL, USA, and Tolmar International Ltd, based in Dublin, Ireland, which together contributed more than EUR 9 million.

芬兰图尔库，2024年1月16日/PRNewswire/--临床阶段药物输送和开发公司DelSiTech今天宣布成功完成1000万欧元的融资回合，这是该公司历史上最大的一轮融资。此次融资由总部位于美国伊利诺伊州芝加哥的new investors DRW Venture Capital LLC和总部位于爱尔兰都柏林的Tolmar International Ltd共同牵头，共出资900多万欧元。

The remaining financing was funded by existing DelSiTech shareholders..

其余融资由现有的DelSiTech股东提供。。

The proceeds from the financing will be used to further build the Company and advance its unique, in-house, silica-based, drug delivery technology platform into clinical development, as well as expanding its in-house manufacturing capability to support the development programs of multiple partners.

融资所得将用于进一步建设该公司，将其独特的、内部的、基于二氧化硅的药物输送技术平台推进临床开发，并扩大其内部制造能力，以支持多个合作伙伴的开发计划。

'We welcome DRW and Tolmar to DelSiTech as new investors and strategic partners at an important time of growth and development.' Said Lasse Leino, Chief Executive Officer at DelSiTech. 'This financing marks a significant milestone on our journey as one of the world's leading drug delivery technology providers, with an attractive internal pipeline of controlled release drug products based on Silica Matrix.

“我们欢迎DRW和Tolmar在增长和发展的重要时刻作为新的投资者和战略合作伙伴来到DelSiTech。”DelSiTech首席执行官拉西·莱诺（LasseLeino）说这项融资标志着我们作为世界领先的药物输送技术提供商之一的旅程上的一个重要里程碑，拥有一条基于二氧化硅基质的有吸引力的内部控释药物产品管道。

This investment, together with our increasing revenues from our own drug development, will help us to reach our strategic business goals and objectives over the next couple of years, as we continue to address high unmet clinical and commercial needs for the benefit of patients.' .

这项投资，加上我们自身药物开发收入的增加，将有助于我们在未来几年实现战略业务目标，因为我们将继续满足患者尚未满足的临床和商业需求。”。

The new investors offered the following comments regarding their commitment to supporting DelSiTech.

新投资者就其支持德尔斯泰克的承诺发表了以下评论。

David Nelson, Partner at DRW, commented: 'We have seen the tremendous importance of strengthening our world's capabilities to bring new treatments online to address viruses and diseases. We have been impressed by the work DelSiTech is doing in this area and by the innovative technologies its team has developed, and we are pleased to join this round to help them accelerate this work.'.

DRW的合伙人大卫·尼尔森（DavidNelson）评论道：“我们已经看到，加强我们世界的能力，使新的在线治疗方法能够解决病毒和疾病，具有极其重要的意义。DelSiTech在这一领域所做的工作及其团队开发的创新技术给我们留下了深刻印象，我们很高兴加入这一轮，帮助他们加速这项工作。”。

Anil D'Souza, President and Chief Executive Officer of Tolmar, remarked: 'This investment further advances Tolmar's overall business strategy to develop therapies for the benefit of patients around the globe. In addition, we are confident that this investment will lead to profitable growth by further leveraging DelSiTech's differentiated technology platform.'.

托尔玛总裁兼首席执行官阿尼尔·德苏扎（AnilD'Souza）表示：“这项投资进一步推进了托尔玛的整体商业战略，为全球患者的利益开发治疗方法。此外，我们相信，这项投资将通过进一步利用DelSiTech的差异化技术平台实现盈利增长。”。

About DelSiTech:

关于DelSiTech：

DelSiTech Ltd., located in Turku, Finland, is the leading technology specialist in biodegradable silica-based controlled release of small molecule drugs, biologics, and vaccines. It develops and commercializes its proprietary drug delivery technology in collaboration with a number of pharmaceutical and biotech companies to turn their ideas into novel drug products.

位于芬兰图尔库的DelSiTech有限公司是可生物降解二氧化硅基小分子药物，生物制剂和疫苗控释的领先技术专家。它与许多制药和生物技术公司合作开发并商业化其专有药物输送技术，将其想法转化为新药。

For more information, see www.delsitech.com..

For more information, see www.delsitech.com..

About DelSiTechTM Silica Matrix

关于DelSiTechTM二氧化硅基质

Silica Matrix is an advanced delivery technology platform for parenteral and local administration of injectable and implant dosage forms as well as eye drops. The proprietary technology is based on silica (SiO2) matrix into which the molecule or therapeutic agent of interest is embedded using a process called sol-gel.

二氧化硅基质是一种先进的输送技术平台，用于注射和植入剂型以及滴眼液的肠胃外和局部给药。该专有技术基于二氧化硅（SiO2）基质，使用称为溶胶-凝胶的方法将感兴趣的分子或治疗剂嵌入其中。

The resulting Silica Matrix is non-porous, biocompatible and it can be designed to biodegrade by matrix dissolution at the desired rate to ensure a tightly controlled release of the active substance over periods of days up to many months or a year..

由此产生的二氧化硅基质是无孔的，具有生物相容性，可以通过基质溶解以所需的速率进行生物降解，以确保活性物质在数天到数月或一年的时间内得到严格控制的释放。。

About DRW Venture Capital, LLC:

关于DRW Venture Capital，LLC：

DRW is a diversified trading firm with decades of experience bringing sophisticated technology and exceptional people together to operate in markets around the world. Headquartered in Chicago, USA, with offices around the globe, we trade a number of asset classes, including Fixed Income, ETFs, Equities, FX, Commodities and Energy.

DRW是一家多元化的贸易公司，拥有数十年的经验，将先进的技术和优秀的人才聚集在一起，在世界各地的市场上运作。总部位于美国芝加哥，在全球设有办事处，我们交易多种资产类别，包括固定收益、ETF、股票、外汇、大宗商品和能源。

For over a decade, we also have been a trusted investor in exciting new projects through DRW Venture Capital, which operates as a subsidiary of DRW. DRW VC is a stage-agnostic investor focused on financial and enterprise technology companies that benefit from the combination of our capital and expertise.

十多年来，我们还通过作为DRW子公司运营的DRW风险投资，成为令人兴奋的新项目的值得信赖的投资者。DRW VC是一家不分阶段的投资者，专注于金融和企业技术公司，这些公司受益于我们的资本和专业知识的结合。

For more information, please visit www.drw.com..

有关更多信息，请访问www.drw.com。。

About Tolmar International Ltd

关于托尔玛国际有限公司

Tolmar is a fully integrated pharmaceutical company focused on the innovative development, manufacturing, and commercialization of specialty pharmaceuticals across multiple therapeutic areas, including Urology. Tolmar's product development and manufacturing facilities are based in Northern Colorado and its executive offices and commercial headquarters are based in Buffalo Grove, Illinois.

Tolmar是一家全面整合的制药公司，专注于包括泌尿外科在内的多个治疗领域的专业药物的创新开发，制造和商业化。托尔玛的产品开发和制造工厂位于科罗拉多州北部，其执行办公室和商业总部位于伊利诺伊州的布法罗格罗夫。

For more information about the company, please visit www.tolmar.com..

有关该公司的更多信息，请访问www.tolmar.com。。

SOURCE DelSiTech

源DelSiTech